Analysts Set Omeros Co. (NASDAQ:OMER) Target Price at $22.50

Shares of Omeros Co. (NASDAQ:OMER - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $22.50.

Several research firms have issued reports on OMER. D. Boral Capital reissued a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research report on Tuesday, May 13th. Wall Street Zen raised shares of Omeros from a "sell" rating to a "hold" rating in a research report on Monday, May 19th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research report on Friday, May 16th.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently bought and sold shares of OMER. Nomura Holdings Inc. lifted its position in Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock valued at $7,383,000 after acquiring an additional 430,932 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in Omeros during the fourth quarter valued at approximately $1,488,000. Wellington Management Group LLP purchased a new stake in Omeros during the first quarter valued at approximately $1,118,000. Nuveen LLC purchased a new stake in Omeros during the first quarter valued at approximately $938,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Omeros during the fourth quarter valued at approximately $1,120,000. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Stock Performance

Omeros stock traded up $0.01 during trading hours on Thursday, hitting $3.17. The company had a trading volume of 672,372 shares, compared to its average volume of 667,890. The firm has a market cap of $185.74 million, a P/E ratio of -1.37 and a beta of 2.42. Omeros has a 1 year low of $2.97 and a 1 year high of $13.60. The company has a 50-day moving average price of $6.31 and a two-hundred day moving average price of $8.08.

Omeros (NASDAQ:OMER - Get Free Report) last released its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05). As a group, equities research analysts anticipate that Omeros will post -3.09 EPS for the current year.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.